Avistone website screenshot

Avistone

Beijing Avistone Biotechnology Co., Ltd. is a commercial-stage innovative biopharmaceutical company headquartered in Beijing, China, focused on the research, development, and commercialization of first-in-class and best-in-class oncology therapies. Founded in 2012 (originally Beijing Pearl Biotechnology) and renamed Avistone in 2018, the company has two approved cancer drugs on the market: Vebreltinib (万比锐®), a MET inhibitor approved for non-small cell lung cancer and glioma indications and included in China's National Reimbursement Drug List, and Andamertinib (安比锐®), an EGFR exon 20 insertion inhibitor approved in 2026 for advanced NSCLC. Avistone maintains a pipeline of additional candidates (ANS01 through ANS09) across solid-tumor indications and is backed by IDG Capital. The company publishes no public developer API or programmatic surface; this profile captures its corporate and investor identity.

Avistone is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biopharmaceutical, Oncology, and Pharmaceuticals.

🌐 Visit website 📡 Source on GitHub
5.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyHealthcareBiopharmaceuticalOncologyPharmaceuticalsDrug DevelopmentBiotechnologyCancer TherapeuticsChina

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 5.0/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 0.8 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/avistone: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 4

The organization behind the API

Website
Website
 Website
Website
 Careers
Careers
 InvestorRelations
InvestorRelations

Source (apis.yml)

apis.yml Raw ↑ 
aid: avistone
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/avistone.png
name: Avistone
description: 'Beijing Avistone Biotechnology Co., Ltd. is a commercial-stage innovative biopharmaceutical company headquartered
  in Beijing, China, focused on the research, development, and commercialization of first-in-class and best-in-class oncology
  therapies. Founded in 2012 (originally Beijing Pearl Biotechnology) and renamed Avistone in 2018, the company has two approved
  cancer drugs on the market: Vebreltinib (万比锐®), a MET inhibitor approved for non-small cell lung cancer and glioma indications
  and included in China''s National Reimbursement Drug List, and Andamertinib (安比锐®), an EGFR exon 20 insertion inhibitor
  approved in 2026 for advanced NSCLC. Avistone maintains a pipeline of additional candidates (ANS01 through ANS09) across
  solid-tumor indications and is backed by IDG Capital. The company publishes no public developer API or programmatic surface;
  this profile captures its corporate and investor identity.'
url: https://raw.githubusercontent.com/api-evangelist/avistone/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- idg-capital
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Healthcare
- Biopharmaceutical
- Oncology
- Pharmaceuticals
- Drug Development
- Biotechnology
- Cancer Therapeutics
- China
apis: []
common:
- type: Website
  url: https://en.avistonebio.com
- type: Website
  url: https://www.avistonebio.com
- type: PrivacyPolicy
  url: https://www.avistonebio.com/privacy_policy.html
- type: Careers
  url: https://www.avistonebio.com/join_index.html
- type: InvestorRelations
  url: https://www.avistonebio.com/investor_index.html
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence